These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 34271080)

  • 21. Medical management of levodopa-associated motor complications in patients with Parkinson's disease.
    Jankovic J; Stacy M
    CNS Drugs; 2007; 21(8):677-92. PubMed ID: 17630819
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cost-Effectiveness of Dopamine Agonists and Monoamine Oxidase B Inhibitors in Early Parkinson's Disease.
    McIntosh E; Kent S; Gray A; Clarke CE; Williams A; Jenkinson C; Ives N; Patel S; Rick C; Wheatley K; Gray R;
    Mov Disord; 2021 Sep; 36(9):2136-2143. PubMed ID: 33960511
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Parkinson's disease. Therapeutic strategies to improve patient function and quality of life.
    Danisi F
    Geriatrics; 2002 Mar; 57(3):46-50; quiz 52. PubMed ID: 11899548
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of rasagiline as adjunct therapy to levodopa on severity of OFF in Parkinson's disease.
    Stocchi F; Rabey JM
    Eur J Neurol; 2011 Dec; 18(12):1373-8. PubMed ID: 21895884
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Meta-analysis of the comparative efficacy and safety of adjuvant treatment to levodopa in later Parkinson's disease.
    Stowe R; Ives N; Clarke CE; Handley K; Furmston A; Deane K; van Hilten JJ; Wheatley K; Gray R
    Mov Disord; 2011 Mar; 26(4):587-98. PubMed ID: 21370258
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The evolution of pharmacological treatment for Parkinson's disease.
    Almeida QJ; Hyson HC
    Recent Pat CNS Drug Discov; 2008 Jan; 3(1):50-4. PubMed ID: 18221241
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Dopamine agonists in Parkinson's disease therapy - 15 years of experience of the Neurological Clinics from Tîrgu Mureș. A cross-sectional study].
    Szász JA; Viorelia C; Mihály I; Biró I; Péter C; Orbán-Kis K; Szatmári S
    Ideggyogy Sz; 2019 May; 72(5-6):187-193. PubMed ID: 31241263
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Modes of drug delivery used to manage Parkinson's disease.
    Noble C
    Nurs Times; 2006 Aug 8-14; 102(32):30-2. PubMed ID: 16922099
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Treatment Strategies in Early Parkinson's Disease.
    Marsili L; Marconi R; Colosimo C
    Int Rev Neurobiol; 2017; 132():345-360. PubMed ID: 28554414
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [The new Parkinson's disease drugs].
    Hasegawa K
    Nihon Rinsho; 2000 Oct; 58(10):2066-71. PubMed ID: 11068448
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Parkinson's disease--levodopa complications.
    King DB
    Can J Neurol Sci; 1999 Aug; 26 Suppl 2():S13-20. PubMed ID: 10451755
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The pharmacology of Parkinson's disease: basic aspects and recent advances.
    Da Prada M; Keller HH; Pieri L; Kettler R; Haefely WE
    Experientia; 1984 Nov; 40(11):1165-72. PubMed ID: 6437857
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Levodopa strengths and weaknesses.
    Jankovic J
    Neurology; 2002 Feb; 58(4 Suppl 1):S19-32. PubMed ID: 11909982
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Neuroprotective approaches to halt Parkinson's disease progression.
    Sola P; Krishnamurthy PT; Kumari M; Byran G; Gangadharappa HV; Garikapati KK
    Neurochem Int; 2022 Sep; 158():105380. PubMed ID: 35718278
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Drug selection and timing of initiation of treatment in early Parkinson's disease.
    Schapira AH; Olanow CW
    Ann Neurol; 2008 Dec; 64 Suppl 2():S47-55. PubMed ID: 19127579
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacokinetic/pharmacodynamic evaluation of rasagiline mesylate for Parkinson's disease.
    Müller T
    Expert Opin Drug Metab Toxicol; 2014 Oct; 10(10):1423-32. PubMed ID: 25196265
    [TBL] [Abstract][Full Text] [Related]  

  • 37. What is the best initial treatment in Parkinson's disease?
    Sharp ME; Mazzoni P
    J R Coll Physicians Edinb; 2014; 44(4):291-2. PubMed ID: 25516899
    [No Abstract]   [Full Text] [Related]  

  • 38. Initiating dopaminergic treatment in Parkinson's disease.
    Lang AE; Marras C
    Lancet; 2014 Sep; 384(9949):1164-6. PubMed ID: 24928806
    [No Abstract]   [Full Text] [Related]  

  • 39. Comprehensive review of rasagiline, a second-generation monoamine oxidase inhibitor, for the treatment of Parkinson's disease.
    Chen JJ; Swope DM; Dashtipour K
    Clin Ther; 2007 Sep; 29(9):1825-49. PubMed ID: 18035186
    [TBL] [Abstract][Full Text] [Related]  

  • 40. 'Bad guys' among the antiparkinsonian drugs.
    Pirtosek Z
    Psychiatr Danub; 2009 Mar; 21(1):114-8. PubMed ID: 19270634
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.